Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesComparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort studyTwelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesDose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS studyClinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.Follow-up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infectionImpact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data.Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohortDrug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapyA personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.Effectiveness of golimumab in clinical management of patients with rheumatoid arthritisCost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockersPersistence with biologic agents for the treatment of rheumatoid arthritis in Japan.Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients.German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis.Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice.EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis.Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment?[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid ArthritisA Case of Peritoneal Tuberculosis Developed after Infliximab Therapy for Refractory RA.Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry.Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus.Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
P2860
Q26778600-278BFD88-68EA-4FAD-9B02-A9C5E47A677DQ28542423-88D482A8-8599-4DB7-9F3F-C1921CB7C6A1Q31021097-E27D3200-CC95-462C-9ABD-E69F242E4595Q33578361-8517C8D6-8AF4-4FC3-8489-9AD51C8EA64AQ33590773-5F95DF63-617F-4FDF-9A23-B7581ACE2A2BQ33608688-D58B2FC3-B3FA-4415-BC8A-D8A127B5750DQ34029954-8A52A332-0F3F-43CE-85BA-627465D82D8DQ34109394-B1E37DCA-8AAE-43F7-AEBF-2474AE854E6CQ34216613-B3C0172C-3FAA-4B68-890E-1332E95B6919Q34264302-DC0E9532-4F05-4687-9EEA-63AC70A54142Q35048347-3F42EF4A-2C25-4CE3-A9F4-48AF3A65F6B7Q35617683-63B396B2-FDDE-41EB-A46F-ABB29CE35740Q35835741-B4F37C5F-F564-4EC5-BA54-CD810DDA35F3Q35842876-30553242-6E96-4A17-BFD1-D2417FADC56CQ35851000-18B599DF-D73F-4370-89D1-FE432032E1F7Q36767782-146208CF-AA57-4337-9CA5-B84CD3BA6A09Q36776326-4DE9C880-BCF5-49BB-A8CC-2B87E90E1B51Q37167818-D4E8A2AA-1A7F-4351-A11C-3AE47C2A815AQ37184062-D2B974C7-6B63-4C7A-AB10-84563B910B8BQ37189376-3CA25AAD-32B7-4BEB-9261-BDB9E9B5DD3CQ37500085-4BF1E736-CF82-4C5E-9DBD-95649DD4E9B7Q38128726-038D2337-6D1D-49F9-AF0E-37F3147AB85DQ38171360-4B976FC1-4F0C-41CA-9EEA-7C9F7B0232EAQ38183297-03C849D3-697A-48E2-BEB9-30E2D6E037B3Q38404761-2255883B-189B-4A62-971C-22F94831D0EFQ38636348-112DB48D-A086-4469-B2F5-120376B32DA6Q38915704-BD3D6CE8-9985-4392-A020-69AF4D81354FQ38921982-0E789CE5-3FD0-46A3-86F9-3E44FFE7F35BQ40179378-0CF68684-AFD7-410C-BECA-77F2A492D9FBQ40597614-2CDA0888-CFEB-407F-BBF7-1E99088A7B4BQ41176187-2D257DEA-B3C2-4300-81BE-FB805C6A52E0Q41200262-7AE736A3-D665-456F-B53F-2E26D197928DQ41372671-0D45C6D8-9DE3-4D38-B503-BDFBE9935F8DQ41693369-C38B7F6C-FEE7-44CB-A2F4-74DA4523CCA8Q42465776-B9963C58-4A76-4F01-ABDA-897B4FC06C6FQ44518151-6309FBB6-CB9D-428F-9EA2-F121CAEDA29CQ46957950-DBE4BCE3-B769-4EE0-B987-0AB8ED6BB738Q47687442-9A9F6314-4E10-4207-832F-5C7C6D7C0EE5Q49370571-0F6798E3-BD9D-4F30-AE9C-E3C6F199876EQ53366166-2BBA30E6-983B-44AE-B562-1925E501672A
P2860
Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Long-term effectiveness and sa ...... Arthritis Monitoring register.
@en
Long-term effectiveness and sa ...... Arthritis Monitoring register.
@nl
type
label
Long-term effectiveness and sa ...... Arthritis Monitoring register.
@en
Long-term effectiveness and sa ...... Arthritis Monitoring register.
@nl
prefLabel
Long-term effectiveness and sa ...... Arthritis Monitoring register.
@en
Long-term effectiveness and sa ...... Arthritis Monitoring register.
@nl
P2093
P2860
P356
P1433
P1476
Long-term effectiveness and sa ...... Arthritis Monitoring register.
@en
P2093
Eddy M M Adang
Henk Visser
Jaap Fransen
Mart A F van de Laar
Piet L C M van Riel
Wietske Kievit
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEQ325
P577
2010-11-14T00:00:00Z